Palisade Bio Reveals Encouraging Preclinical Outcomes for PALI-2108
Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company, made headlines by showcasing positive preclinical data for its therapeutic candidate, PALI-2108. Presenting at the Crohn's & Colitis Congress, Palisade highlighted the drug's potential to significantly alleviate symptoms of ulcerative colitis (UC) while maintaining a favorable safety profile.
Insights from the Recent Presentation
The results were shared through a poster titled 'PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model.' The findings reveal the drug's effectiveness in reducing inflammation and disease activity in an animal model of colitis.
Significant Drug Benefits
PALI-2108 stands out for its innovative mechanism as an oral, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug. The development aims to offer new treatment possibilities for patients seeking better remission rates and reduced systemic immunosuppression, crucial factors in managing UC.
Expert Commentary
Dr. Mitch Jones, the Chief Medical Officer of Palisade Bio, expressed optimism about PALI-2108, stating, 'UC patients need new oral therapies with higher remission rates, less systemic immunosuppression, and a strong safety profile. We continue to be encouraged by our preclinical and clinical results for PALI-2108.' He conveyed enthusiasm about the upcoming topline data set to be released soon.
Research Methodology and Findings
The studies involved treating mice with induced colitis with PALI-2108 for three consecutive days. Samples were taken from various gastrointestinal regions to assess drug concentration and its engagement with PDE4 targets. Remarkably, PALI-2108 not only showed significant disease activity reduction but also outperformed traditional therapies like tacrolimus and apremilast.
Pharmacokinetic Dynamics
Furthermore, pharmacokinetic modeling derived from both UC patients and healthy volunteers demonstrated PALI-2108’s favorable absorption and bioavailability. This research supports potential clinical applications and feasibility of treatment.
Noteworthy Highlights from the Study
Several key findings have emerged from the recent studies:
- PALI-2108 effectively alleviated colitis symptoms without causing central nervous system toxicity, making it a unique contender for treating UC.
- The drug converts to the active form, PALI-0008, specifically in the colon after being administered orally, a promising trait for targeted therapies.
- In preclinical tests, PALI-2108 exhibited superior efficacy compared to existing PDE4 inhibitors.
- The dosing regimen is particularly advantageous, with modeling allowances suggesting twice-daily doses during induction and once-daily during maintenance.
- No systemic safety issues arose across comprehensive trials involving various animal models, including dogs and monkeys.
Current Clinical Studies
At present, Palisade Bio is engaged in a Phase 1a/b single-center, double-blind, placebo-controlled clinical trial that assesses the safety and pharmacodynamics of PALI-2108. An additional open-label study involving UC patients is also part of the ongoing research efforts. This multifaceted approach underscores the commitment to understanding PALI-2108’s full therapeutic potential.
About Palisade Bio
Palisade Bio is dedicated to creating innovative therapeutic solutions for patients battling autoimmune, inflammatory, and fibrotic diseases. By focusing on targeted treatment options, the company aspires to reshape the current therapeutic landscape for these challenging conditions.
Frequently Asked Questions
What is PALI-2108?
PALI-2108 is an orally administered, colon-specific PDE4 inhibitor prodrug developed by Palisade Bio for treating ulcerative colitis.
What were the main findings presented at the Crohn’s & Colitis Congress?
Palisade Bio demonstrated that PALI-2108 effectively reduces colitis symptoms in a mouse model without CNS toxicity.
What are the benefits of PALI-2108 over other treatments?
PALI-2108 shows superior potency, targeted action, and a favorable safety profile compared to standard treatments like tacrolimus and apremilast.
What is the current stage of clinical trials for PALI-2108?
Palisade is currently conducting a Phase 1a/b clinical study focusing on its safety and efficacy in healthy volunteers and UC patients.
How can I learn more about Palisade Bio's research?
For detailed updates and information regarding PALI-2108 and other developments, please refer to Palisade Bio's official communications.
